Incyte Corp insider trades: Agenus (AGEN) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Incyte Corp reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 17, 2020 | AGEN | ↓ Sell | 214,000 | $3.66 | $783K | Direct | Jun 18, 2020 (1d) |
| Jun 15, 2020 | AGEN | ↓ Sell | 577,000 | $3.64 | $2.1M | Direct | Jun 15, 2020 (0d) |
| Feb 14, 2017 | AGEN | ↑ Buy | 10,000,000 | $6.00 | $60.0M | Direct | Feb 14, 2017 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Incyte Corp's insider trades
Incyte Corp is a 10% owner of Agenus (AGEN). Since Feb 14, 2017, it has reported 1 open-market purchase worth $60.0M and 2 sales worth $2.9M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGEN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.